{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"25.9","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Tumor response was evaluated via Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and response rate was defined as the proportion of patients with a complete response or partial response among all eligible and treated patients. Complete response was defined as disappearance of all tumor lesions. Partial response was defined as at least a 30% decrease in the sum of the longest diameters of target lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients progressed on bortezomib in step 1 crossed over to the combination arm. Response rate is evaluated in these patients.","id":"OG000","title":"Cross-over From Bortezomib to Combined Arm"}],"paramType":"NUMBER","populationDescription":"10 eligible and treated patients who progressed on bortezomib and crossed over to bortezomib and irinotecan arm were included in the analysis","reportingStatus":"POSTED","timeFrame":"Tumor response was assessed after every 2 cycles until progression or intolerable toxicity with maximum of 3 years","title":"Response Rate on Step 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}